Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

BRAF-targeted therapy results in objective responses in the majority of patients, however the responses are short-lived (~6 months). In contrast, treatment with immune checkpoint inhibitors results in a lower response rate, but the responses tend to be more durable. BRAF inhibition results in a more...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cooper, Zachary A., Juneja, Vikram R., Sage, Peter T., Frederick, Dennie T., Piris, Adriano, Mitra, Devarati, Lo, Jennifer A., Hodi, F. Stephen, Freeman, Gordon J., Bosenberg, Marcus W., McMahon, Martin, Flaherty, Keith T., Fisher, David E., Sharpe, Arlene H., Wargo, Jennifer A.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4097121/
https://ncbi.nlm.nih.gov/pubmed/24903021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0215
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars